Latest developments in metal complexes as anticancer agents

Renata Paprocka, Małgorzata Wiese-Szadkowska, Sabina Janciauskiene, Tomasz Kosmalski, Marcelina Kulik, Anna Helmin-Basa

Research output: Contribution to journalReview articlepeer-review

10 Citations (SciVal)


Every year novel biologically active compounds are designed as antitumor agents. This review covers and highlights some of the most important findings described during 2018–2020 to appoint the benefits and drawbacks regarding the activity and toxicity of the metal-based cancer drug candidates. We review new multi-action platinum(IV) prodrugs and other metal complexes with high chemotherapeutic potential, which are designed to overcome cisplatin-resistant cancer cells. We also overview new complexes of Os(II), Ru(II), Ir(III), and Zn(II) used for photodynamic therapy, as well as the complexes conjugated with conventional drugs exhibiting new mechanisms of action. Promising complexes that exceed the selectivity of cisplatin, highly effective in vitro and in vivo, against certain types of neoplasms are distinguished in the lung, colon, liver, stomach, breast cancers and others.

Original languageEnglish
Article number214307
JournalCoordination Chemistry Reviews
Publication statusPublished - 2022

Subject classification (UKÄ)

  • Cancer and Oncology


  • Antitumor activity
  • Cisplatin
  • Cytotoxicity, in vivo
  • Photodynamic therapy
  • Prodrug


Dive into the research topics of 'Latest developments in metal complexes as anticancer agents'. Together they form a unique fingerprint.

Cite this